ibogaine eligibility screening

The Pre-Treatment Screening Process: What Makes You a Candidate (Or Not)

Ibogaine is a powerful medical intervention. One of the most important indicators of a safe and ethical ibogaine program is a rigorous screening process that determines who is a candidate and who is not.

At Bassé Ibogaine Treatment Center, screening is the foundation of safety. Many people who inquire about treatment are surprised to learn that ibogaine eligibility screening is designed as much to rule people out as it is to approve them.

This guide explains how ibogaine medical screening works, what the absolute and relative contraindications are, and what to expect from the comprehensive assessment process before treatment is ever scheduled.

Why Ibogaine Eligibility Screening Matters

Ibogaine interacts with the heart, liver, and central nervous system. It also interacts with a wide range of medications. Because of this, it cannot be administered safely without understanding a person’s full medical picture.

Reputable clinics do not attempt to “fit” people into treatment. They assess whether treatment fits the person.

Ibogaine pre-treatment requirements exist to prevent avoidable medical emergencies and to ensure that the benefits of treatment outweigh the risks.

Absolute Contraindications: Who Cannot Take Ibogaine

There are certain conditions under which ibogaine should not be administered under any circumstances. These are known as absolute contraindications.

People with the following are not candidates for ibogaine:

  • Prolonged QT interval or serious cardiac arrhythmias
  • History of significant heart disease or cardiomyopathy
  • Uncontrolled seizure disorders
  • Advanced liver failure or severe hepatic impairment
  • Certain inherited cardiac conduction disorders
  • Inability to discontinue medications that dangerously interact with ibogaine

These ibogaine contraindications are non-negotiable. Proceeding despite them would be medically irresponsible.

Relative Contraindications: Conditions That Require Management

Some conditions do not automatically disqualify someone but require careful medical planning and stabilization.

These include:

  • Long-term benzodiazepine use
  • Antidepressant use (SSRIs, SNRIs, MAOIs)
  • Electrolyte imbalances
  • Mild to moderate liver enzyme elevation
  • History of alcohol withdrawal complications
  • Co-occurring medical conditions requiring monitoring

In these cases, medical clearance for ibogaine may still be possible, but only after appropriate tapering, stabilization, or specialist consultation.

What If I’m Taking Antidepressants?

This is one of the most common questions in ibogaine eligibility screening.

Many antidepressants interact dangerously with ibogaine, particularly SSRIs, SNRIs, and MAOIs. These medications must be discontinued well in advance of treatment to avoid serotonin toxicity or cardiac complications.

Discontinuation must be done gradually and under medical supervision. Abrupt cessation can cause withdrawal symptoms or psychiatric destabilization.

Ibogaine should never be administered while antidepressants are still active in the body.

Bassé’s Three-Phase Screening Process

To ensure safety, Bassé uses a structured three-phase comprehensive ibogaine assessment.

Phase 1: Initial Intake

The process begins with a detailed intake questionnaire covering:

  • Medical history
  • Psychiatric history
  • Substance use history
  • Current medications and supplements

This phase identifies immediate red flags and determines whether further screening is appropriate.

Phase 2: Medical Review

If the initial intake suggests potential eligibility, a full ibogaine medical screening is conducted.

This includes:

  • ECG/EKG results
  • Blood work (liver enzymes, kidney function, electrolytes)
  • Medication interaction review
  • Cardiac risk assessment
  • Seizure history evaluation

Physicians review this information to determine whether treatment is safe, needs modification, or must be declined.

Phase 3: On-Site Assessment

Even after provisional approval, final clearance occurs on site.

Vital signs, cardiac rhythm, hydration status, and neurological stability are reassessed before any ibogaine is administered. If anything has changed, treatment may be postponed or canceled.

Safety decisions are made in real time.

Ibogaine Health Requirements Are Not Negotiable

Some people view screening as an obstacle. In reality, it is a form of protection.

Ibogaine health requirements are not flexible guidelines. They are medical safeguards based on decades of clinical data and adverse-event analysis.

Clinics that minimize screening or promise acceptance before reviewing medical records should be avoided.

What Happens After You Contact Us: A Timeline

Understanding the process and the programs we offer helps set realistic expectations:

Week 1: Initial inquiry, intake forms, preliminary review
Week 2: Medical records, ECG, blood work submitted
Week 3: Physician review and clearance decision
Week 4+: Medication tapering or stabilization if required

For some people, this process is quick. For others, it may take weeks. Speed is never prioritized over safety.

Why Reputable Clinics Turn People Away

One of the strongest trust indicators in ibogaine care is a clinic’s willingness to say no.

Turning someone away is not a failure. It is an ethical decision when risk exceeds benefit or when alternative treatments are more appropriate.

Responsible screening protects:

  • The individual
  • The medical team
  • The legitimacy of ibogaine therapy

A Safety-First Approach to Healing

Ibogaine can be transformative, but only when used responsibly.

Ibogaine eligibility screening exists to ensure that those who receive treatment can do so with the highest margin of safety possible.

At Bassé, screening is not a hurdle to overcome. It is a clinical commitment to doing this work correctly.

Contact our medical team to begin a comprehensive ibogaine eligibility screening and determine whether treatment is appropriate for you.